newsfilter
← Earnings
Earnings Releases·

Boston Scientific — Third Quarter 2026 Earnings Summary

  • Q3 2026 net sales reached $5.138 billion (up 1.5% YoY), while GAAP net income declined to $582 million ($0.40/share) from $755 million ($0.51/share) and adjusted EPS fell to $0.73 from $0.75, driven by $144 million in combined litigation and restructuring charges.
  • Full-year 2026 guidance was updated to estimate net sales growth of 4.25% (reported) and 3.75% (organic), with adjusted EPS projected between $3.16 and $3.18; Q4 2026 sales are forecast to decline 1.0% to 3.0% with adjusted EPS of $0.77 to $0.79.
  • Strategic progress includes FDA clearances for the Navigator™ Flex Sheath Set and LithoVue™ Elite, Category I CPT code approvals for renal denervation and tibial nerve stimulation effective 2028, and a new AI collaboration with Heartflow, Inc.
  • Segment performance was mixed, with Neuromodulation leading at 13.1% growth and LACA expanding 16.0%, while Endoscopy and Urology declined 0.8% and 3.2% respectively, amidst a significant cybersecurity incident in August 2026.
Company
BOSTON SCIENTIFIC CORP
Sector
Healthcare
Industry
Medical Devices